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2

COATED PRODUCTS WITH POTENT
ANTI-HIV AND ANTIMICROBIAL
PROPERTIES

Liebert, M. A., (1983) J. Am. Coll. Toxicol. 2: 35-60). As the
length of the E0 chain increases, the oligomers increase in

water solubility. Nonoxynol-9 oligomers 1 through 6 (n=1—
6) are considered oil soluble compounds, whereas the oli
gomers with a longer EO chain are soluble in water and

This application is a continuation in part application of
U.S. Ser. No. 08/106,948 ?led Aug. 17, 1993, now U.S. Pat.
No. 5,380,523.

polar organic solvents (see Liebert, supra).
These di?erences in chemical properties of N9 oligomers

TECHNICAL FIELD
10

aifect their biological behavior both in vitro and in vivo. For
instance, it was noted that the dermal toxicity of nonoxynol‘
decreases as the molecular weight increases (see Liebert,

I. The present invention relates to a composition with

supra) and that smaller molecular weight nonoxynol may be

potent anti-HIV activity. The composition is a high energy

more toxic to ?broblasts than the larger ones (see Chvapil,
M. et al., (1980) Fertil. Steril. 33: 521-525).

coprecipitate of nonoxynol oligomers, polyvinylpyrrolidone
(PVP) and iodine and shows a pronounced synergistic e?ect
between the compounds of the composition.

The in vitro sperrnicidal activity of the N-9 surfactant is
also related to its molecular weight. Thus the oligomer n=9
15

II. The invention also relates to products coated with the

high-energy coprecipitate composition, particularly to
coated paper products, including surgical gowns and hospi
tal linens.
III. The invention additionally relates to products coated

when separated from the N9 compound, was much more

effective in inhibiting the motility of the spermatozoa than

the higher molecular weight nonoxynols where n=30, 50,
and 100. (See Chvapil, M. et al., (1980) Fertil. Steril. 33:
521-525.) The lower molecular weight nonoxynols (n=1 or
20

4) could not be studied appropriately because of their poor

solubility in the aqueous testing medium (see Chvapil,

with the high-energy coprecipitate composition, particularly
to plastic products, including surgical gloves and prophy»

supra).

lactics.

Analogous dependence on molecular weight was
observed in vivo. Oral absorption studies in the rat indicated
BACKGROUND

25

Nonoxynol or nonylphenol(polyethoxy)ethanol is a non

ionic surfactant used as the active ingredient in the majority
of the commercially available spermicides. It inhibits the in
vitro growth of venereal pathogens (see Benes, S. et al.,
(1985) Antimicrob. Agent Chemothen 27: 724-726; Kelly, J.
P. et al., (2985), Antimicrob. Agent Chemother 27: 760-762;

the vaginal membrane was poor and re?ects the preferential

absorption of lyophilic low molecular weight oligomers.
(See Walter, B. A. et al. (1988) Toxicol. Applied Pharmacol.

96: 258-268.)
An e?icient high pressure liquid chromatography (HPLC)

Austin, H., et al., (2984) JAMA, 251: 2822-2824; and Singh,
B. et al., (1972) Br: J. Vener. Dis. 48: 57-64), including the
herpes simplex viruses (see Asculai, S. S. et al., (1978)
Antimicrob. Agent Chemother: 13: 686-690; Hicks, D. R.,
(1985) Lancet, 1422-1423; Friedman-Kein, (1986) J. Am.
Acad. Dermal. 15: 989-994; Rapp, R. et al., (1985) Anti
microb. Agent Chemother. 28: 449-451; Voeller, B., (1986)
Lancet, 1153; Malkovsky, M. et al., (1988) Lancet, 645; and
Barbi, M. et al., (1987) Ball. 1st. Sieroter. (Milan) 66:

that increasing the length of the ethylene oxide chain
decreased N-9 oligomer intestinal absorption (see Knaak, J.
B. et al., (1966) Toxicol. Appl. Pharmacol. 9: 331-340).
Furthermore, data showed that absorption of N9 through

method for the separation of [14C] N9 and characterization
of the oligomeric components of the spermicide N~9 has
been developed. (See Walter, B. A. et al. (1988) Toxicol.
Applied Pharmacol. 96: 258-268; and Walter, B. A. et al.,
(1991) Pharm. Res. 8: 409-411).
Utilizing this normal phase gradient elution HPLC
40

method, at least seventeen oligomers were isolated from

commercial N-9. Selected oligomers representing the high,

158-160).

medium and low molecular weight fraction of N-9 were

By the nature of its synthesis, the nonoxynol-9 (N-9)
(Igepal CO-630) derivative of nonoxynol is a polymer
consisting of at least 17 oligomers of varying ethylene oxide
(E0) chain length. The molecule of N-9 contains a hydro

separated in milligram quantities by normal phase gradient
HPLC (see Walter, B. A. et al., (1991) Pharm. Res. 8:
409-41'1; and Walter, B. A. et al., (1991) Pharm. Res. 8:

403-408).

phobic moiety (nonylphenol portion) and a hydrophilic

Polyvinylpyrrolidone (also known as povidone USP) is

chain composed basically of ethylene oxide units. The

one of the most highly utilized polymers in medicine

compound is a product of a statistical polymerization reac
because of its safety for human use and unique hydrophilic
tion of 9 moles of ethylene oxide and one mole of non 50 properties (see Robinson, B. V. et al. (1990), A critical

ylphenol (see equation below):

review of the Kinetics and Toxicology of Polyvinyl-pyrroli
done, Lewis Publishers, Inc., Michigan).

0

CgHrg

on + rrzc

\

Discovered and used during World War II as a plasma

Na“
CH1 %
55

expander, PVP is currently used as excipient in many
pharmaceutical preparations intended for external use (e.g.
povidone-iodine USP solutions such as Betadine); for oral
use, such as a solubilizing agent and tablet disintegrant, and
for vaginal use such as in PVP-I douche.
Several studies have focused on the dissolution rate

60

Nonoxynol-9 (N-9)

where “n” represents the number of ethylene oxide units.
The above reaction does not yield a distinct compound but
a mixture of oligomers with different molecular weights.
The physical and chemical characteristics of these oligomers
change as a function of the varying molecular weight. (See

65

behavior of drug-povidone coprecipitates. (See Higuchi, W.
I. et al., (1983) in Proceedings of the International Sympo
sium on Povidone, Digenis, G. A. and Ansell, J., Eds.
Lexington, pp. 71-79; Simonelli, A. P. et al., (1987) in
Proceedings of the 2nd International Symposium on Povi
done, Digenis, G. A. and Agha, B. J., Eds., Lexington, pp.
392-401; Simonelli et al., (1969) J. Pharm. Sci, 58:
538-549; Simonelli et al. (1976) ibid. 65: 355-361.)

5,492,692
4

3
These studies found that the preferential dissolution of

pared to their counterparts that were prepared from higher

one component (hydrophilic polymer, such as PVP) can
enhance the dissolution of the other component in a copre

molecular weight N-9 oligomeric fractions. However, they
were themselves elfective spermicides. The above ?ndings
concluded that when N-9 is coprecipitated with PVP its
spermicidal activity is enhanced. While PVP alone has no
inherent sperm toxicity, the formation of N-9/PVP com

cipitate.
Drug/PVP high energy coprecipitates can be described as
a drug incorporated into a solid PVP solution. Drug release
from PVP coprecipitates are shown to follow dissolution

plexes seem to produce a synergistic response which causes
a more rapid damage to the sperm than any of the two

kinetics of the polymer carrier of PVP provided that the PVP

materials alone (Walter, B. A. et al., (1991) Pharm. Res. 8:

solvent uptake or swelling proceeds freely without inhibition

by the drug.
Mayersohn and Gibaldi (Mayersohn M. et al., (1966) J.
Pharm. Sci. 55: 1323-1324) showed greatly enhanced dis
solution of the antibiotic griseofulvin when the drug was
coprecipitated with povidone (PVP). Higuchi et al. investi
gated a povidone/sulfathiazole system and suggested that the

10

Nonoxynol-9 (N-9) has been shownto be useful in the

prophylaxis against sexually transmitted diseases (STD).
(See Bird, K. D., (1991) AIDS 5: 791-796; and Louv, W. C.
et al., (1988) J. Infect. Dis. 158: 518-523).
More recently, this spermicide has been shown to be
15

resultant enhanced aqueous solubility of sulfathiazole was
due to a high energy state of the drug in the PVP coprecipi
tate resulting in a supersaturated form of the drug after
introduction into aqueous media. (See Higuchi, W. I. et al.,

(1983) in Proceedings of the International Symposium on
Povidone, Digenis, G. A. and Ansell, J., Eds. Lexington, pp.

403-408).

effective against cell-associated HIV at concentrations of

20.05% (v/v). (See Hicks, D. R. et al., (1985) Lancet, ii:

1422-1423; Vopeller, B., (1986) Lancet, i: 1153; and Malk»
ovsky, M., Newell, A., Dalgleish, A. G., (1988) lancer, i:

645).
20

71-79.)

Unfortunately, N-9 causes epithelial disruption of the
cervix and vagina when administered in high doses and high
frequency (see Niruthisard S. et al., (1991) Sex. Transm. Dis.

Simonelli et al., envisioned a PVP/drug coprecipitate

18: 176-179). Higher rates of new IHV infections were

model consisting of two components including the drug in
amorphous state and PVP. (Simonelli, A.P. et al., (1987) in
Proceedings of the 2nd International Symposium on Povi
done, Digenis, G. A. and Agha, B. J., Eds., Lexington, pp.
392-401; Simonelli et al., (1969) J. Pharm. Sci. 58:
538-549; Simonelli et al. (1976) ibid. 65: 355-361.)
The in vitro spermicidal activity of three molecular

found in prostitutes who used N-9 at great frequencies (see
Kreiss, J. et al., International Conference on AIDS, Mont
real, June 1989 [Abstract MAO36]). This observation was

weight fractions of N -9 were compared to that of N-9, using
rabbit spermatozoa, at equimolar concentrations. nonox
ynol-9/PVP complexes were found to be far more effective
in immobilizing the sperm than either N-9 alone or in the
separate fractions (Walter, B. A. et al., (1991) Pharm. Res.

25

attributed to the high incidence of genital ulceration caused
by high doses of N-9, in this group of women. Thus, the
above ?ndings tend to suggest that novel spermicide for—
30

The antimicrobial properties of povidone-iodine (PVP-I),
35

8: 403-408).
The spermicidal activities of three oligomeric fractions of
N-9 with human sperm have been assessed. Equimolar
concentrations of three different molecular weight fractions
of N-9 coprecipitated with PVP were used. These equimolar
concentrations were 166 ug/ml for high molecular weight

(HMW), (MW=599), 123 pg/ml for middle molecular
weight (MMW) (MWI499) and 85 uglml for low molecular
weight (LMW) (MW=306) N-9 fractions. The order of
e?icacy in immobilizing the human spermatozoa was

40

45

irritation properties and are relatively non-toxic (see
LaRocca, R. et al., (1983) in Proceedings of the International
Symposium on Povidone, Digenis, G. A. and Ansell, J., Eds.

Lexington, pp. 101-119).
Stable, sterile (0.2%) PVP-I compositions containing as
50

decline in percentage motility over the course of the test.

Chvapil et al. recognized that the n? oligomeric fraction
of nonoxynol-9 was more etfective in inhibiting the motility
of spermatozoa than the higher molecular weight nonox
ynols. Chvapil et al., however, were unable to study the
lower molecular weight oligomers (n=l-4) because of their
poor solubility in aqueous media.

a complex of polyvinyl pyrrolidone and iodine, have been
well documented. PVP-I solutions (10% w/v) USP are
among the most widely utilized antimicrobial agents. A 10%
(w/v) solution of PVP-I contains 1% (w/v) of available
iodine (12). The microbiological potency of PVP-I arises
from the elemental (diatomic) or free iodine (I2) in solution.
The signi?cant characteristic of iodophors, such as PVP-I, is
that they carry almost all of their iodine in a complexed
forrnso that the amount of free iodine (I2) is quite low and
PVP-I serves as the iodine reservoir delivering the free
iodine into the solutions. Thus, iodophors exhibit reduced

HMW(MW=599)>MMW(MW:499)>LMW(MW:306)
with complete sperm immobilization observed with PVP
coprecipitated with N-9 HMW within 4.0 minutes and PVP
coprecipitated with N9 MMW within 15 minutes after
exposure. Furthermore, addition of the spermicides inter
fered with the progressive motility and linearity of the sperm
swimming pattern. PVP and buifer controls showed no

mulations containing N-9 should be e?icacious at the small
est possible doses so that the integrity of the vaginal epi
thelium is not compromised.

55

little as 0.02% iodine have been shownto be useful in
treating eye infections in humans. A level of 0.02% iodine
obtained by diluting a commercial 10% PVP-I solution at

1:50 with saline solution, is generally considered to be
optimum to maximize performance and rninirrrize irritation
(see Winicov, M. et al., (1987) in Proceedings of the
International Symposium on Povidone, Digenis, G. A. and
Ansell, J ., Eds. Lexington, pp. 57-64).

In contrast, however, Walter et a1. were able to solubilize 60

the water insoluble lower molecular weight N-9 oligomers

Data has shown that with doubly labeled 1“C-PVP-T-“I
solutions the amount of iodine delivered into gram positive
and negative bacteria cultures was three times greater when
the iodine was complexed with PVP, than from an equimolar

by complexing them with the hydrophilic polymer polyvi

solution of 131I3- (Lugol’s solution). (See Digenis, G. A. et

nylpyrrolidone (PVP). (See Walter, B. A. et al., (1991)

al., (1983) in Proceedings of International Symposium on
Povidone, Digenis, G. A. and Ansell, J., Eds. Lexington, pp.

Pharm. Res. 8: 403-408.)

The resulting high energy coprecipitate complexes of the
low molecular species of N-9 were found to be at least
eifective spermicides at all concentrations tested when com

65

302-311).
The hydrophilic polymer PVP acts as a delivery system
for iodine probably due to the membrane seeking properties

5,492,692
5

6

of this polymer. Ben-David and Gavendo have shown that
PVP at 4.6% w/v concentrations protect red blood cells from

embodiment has been modi?ed so that a spermicide such as

nonoxynol-9 is slowly released. Nuwayser does not disclose
PVP-I in combination with nonoxynol-9.

osmotic fragility and mechanical injury. (See Ben-David A.
et al., (1972) Cryobiology, 9: l92—197). These workers
suggested that this effect is brought about by a “coating” or

U.S. Pat. No. 4,954,351 to Sackler et al. discloses a

method of producing standardized povidoneiodine prepara
tions. The patent discloses that the povidone-iodine solution

external interaction of PVP with cell membranes.

The membrane-seeking properties of PVP suggest that in

can be incorporated into a suppository with 0.1 to 10% by
weight of povidone-iodine. Sackler et al. do not disclose the
use of povidoneiodine in combination with nonoxynol-9.

addition to its contribution to the solubilization ability of

N-9, the PVP polymer, via its cell—membrane coating prop‘
erties, also provides vaginal and cervical surface coverage
coating with N9 and iodine over extended periods of time.
In addition to its antimicrobial properties, PVP-I has been
shown to inactivate HIV. (See Kaplan, J. C. et al. (1987)
Infect. Control 8: 412-424; and Harbison, M. A. et al.,

10

and gossypol is an effective spermicide. The patent discloses
that a PVP-gossypol combination when compared to a

comparative example of nonoxynol-9 alone, exhibited equal

(1989) J. Acquir. Immune De?c. Syndr: 2: 16-20). The

or greater spermicidal properties. Waller does not disclose
PVP-I in combination with nonoxynol~9.

concentration of iodine used in Kaplan’s studies was equal
to 0.025% for 250 ppm of I2.
A 0.02% w/v (200 ppm) solution of iodine is considered
non-toxic and non-irritating and is used for treatment of eye
infections in humans. (See Winicov, M. et al., (1987) in

U.S. Pat. No. 4,925,033 to Stoner et al. discloses a

rnicrobicidal cleanser/barrier kit. One method of the inven

tion involves applying a solution of povidone-iodine (PVP
I) to vaginal sponges or condoms. In another embodiment
the povidone-iodine active ingredient may be added to
spermicidal birth control compounds. Stoner et al. disclose
that nonoxynol-9 is a known spermicidal compound. Stoner

Proceedings of the International Symposium on Povidone,
Digenis, G. A. and Ansell, J., Eds. Lexington, pp. 57—64). In
fact, the increased bactericidal activity of dilute solutions of

et a1. do not disclose or suggest the particular combination

povidoneiodine (Betadine - 10% w/v PVP'I) have recently

been well documented. Betadine contains 10,000 ppm (or
10,000 pg/ml) of available iodine and is often irritating to
the tissues and has an undesirable brown color. (See Ber
kelman, R. L. et al., (1982) J. Clin. Microbiol. 15: 635-639.)
At concentrations of about 0.02% w/v of iodine, the unde

25

concern in the United States where 37% of AIDS cases are

male. Moreover, the frequency of global heterosexual trans
mission is probably greater where it is estimated to exceed

None of the prior research in this area recognized the
synergistic anti-HIV result of all three compounds when

60% of all AIDS cases.

It has been suggested that a major contributing factor to
35

Furthermore, spermicides containing nonoxynol-9 and

HIV should be an eifective barrier to transmission.

delivering a medicament to the vaginal cavity consisting of

The exposure to blood borne pathogens has always been
of great concern to the community of individuals whose

a molded sheath of a mixture of a polymeric material and a

occupations require physical contact with tissue and body

medicament. The medicament which is dispersed in the
polymeric material can be nonoxynol-9. The polymer may
be selected from modi?ed cellulose, polyvinyl alcohol,

?uids and this concern has been heightened due to increase

polyvinylpyrrolidone, polyacrylic and ethylene oxide poly
mer. Williams does not disclose the use of PVP-I in com 45

bination with a nonoxynol-9.
U.S. Pat. No. 5,156,164 to LeVeen et al. discloses that
iodine can be dissolved in alcohol containing nonoxynol in
a complex with polyurethane. LeVeen et al. disclose that a

in the incidence of HIV. Current Occupational Safety and
Health Administration (OSHA) standards regarding blood
borne pathogens require the use of gloves in the processing
and handling of any blood and/or body ?uids.
There is a need in the pharmaceutical area for a paper

products and plastic products coated with the antiviral
composition of the invention.
50

treating resistant vaginitis. LeVeen et a1. do not disclose or

The composition of the invention meets the above objec
tives and provides a high energy coprecipitate of nonox

ynol-9 oligomers, polyvinylpyrrolidone and iodine (PVP-I).

suggest combining PVP-I with nonoxynol.

The composition shows a pronounced synergistic effect

U.S. Pat. No. 5,070,889 to Leveen et al. discloses a

contraceptive sponge and tampon made of polyurethane
iodine complex. Leveen et al. teaches away from the use of

heterosexual transmission of HIV is the presence of cell-free

virus and virus-infected cell (cell-associated virus) in genital
secretions. Thus, vaginal contraceptives, which inactivate

polyvinylpyrrolidone or polyurethane are known.
U.S. Pat. No. 4,317,447 to Williams discloses a device for

polyvinylpyrrolidone~iodine complex has been eifective in

of components in the form of a high energy coprecipitate,
nor that the compounds show a synergistic anti-HIV effect.
Heterosexual transmission of human immunode?ciency
virus (HIV), the causative agent of AIDS, is a growing

heterosexually transmitted, the majority being male-tofe

sirable brown color of iodine is not a problem since in dilute
solutions the color is hardly seen and the amount of iodine
is not irritating to tissues.

formulated into a high energy coprecipitate.

U.S. Pat. No. 4,297,341 to Waller et al. discloses that a

water-soluble complex comprising polyvinylpyrrolidone

between the compounds which results in potent anti-HIV
55

activity.

povidone iodine or use as a contraceptive.

U.S. Pat. No. 5,073,365 to Katz et al. discloses clinical
and personal care articles enhanced by lubricants and adju

DISCLOSURE OF THE INVENTION
It is an object of the invention to provide a novel and

vants. The devices can bev made of polyvinylpyrrolidone or

potent composition possessing pronounced anti-HIV prop

polyurethane interpolymers. The device may take the form
of vaginal diaphragms, tampons, condoms or cervical caps.
The medicament may be nonoxynol-9. Katz et al. disclose
that the personal care articles may prevent the transmission

of venereal diseases, possibly including AIDS.
U.S. Pat. No. 4,707,362 to Nuwayser discloses a sustained
release composition made of synthetic polymers such as
polyvinylpyrrolidone. The bioerodible material in one

65

erties which is a high energy coprecipitate composition
comprising N-9 oligomers and PVP and iodine. The PVP
and iodine ingredients may be present in the coprecipitate
composition as the complex PVP-I.
The invention further provides a high energy coprecipitate
composition which is in the form of a powder. In a preferred
embodiment the invention provides a high energy copre

5,492,692
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8

cipitate composition including PVP-I which comprises

of the individual ingredients to achieve the desired anti-HIV

about 0.09—9% w/w of iodine.
In yet another embodiment, the invention provides a high

result, than if the compounds were to be administered as a
mixture. This is bene?cial as it reduces irritation to tissues

energy coprecipitate composition of N-9 complexed with
PVP comprising an antiviral concentration of free iodine of
about 0.03% w/v or about 300 ppm.

caused by higher doses of N-9 and iodine and thus reduces
the potential for HIV virus transmission.
The high energy coprecipitates of the invention are for

The invention additionally provides a high energy copre

mulated by fractionating commercially available spermi~

cipitate composition of N-9 complexed with PVP compris

cide, N-9, into seventeen oligomers by a preparative high

ing an antiviral concentration of free iodine providing about
9.4 to 0.09% I2 providing an effective concentration of free
iodine of 0.0094% w/v (94 ppm) and from about 11.8 —5.8%
w/w of N9 providing an effective concentration of N9 of

pressure liquid chromatography (HPLC) procedure.

10

Selected oligomers of N-9, or the commercially available
N-9, are converted to high energy coprecipitates with PVP
and various amounts of iodine (PVP-I). In a preferred
0.0058% w/v (58 ppm).
embodiment the amount of iodine is about 0.09—9% w/w of
In a further embodiment, the invention includes a high 15 iodine. The content of N-9 in the above complexes, in a
energy coprecipitate composition comprising an eifective
preferred embodiment, ranges from 5.8-1 2% w/w.
?nal concentration of from about 58 pg/ml-ZOO pg/ml of
N-9 and its oligomeric components are inherently viscous
N-9.
liquids which are converted to free ?owing, water soluble
The invention advantageously provides for a method of
powders by forming coprecipitates with PVP-l. Several

preparing a high-energy coprecipitate composition compris

combinations of iodine (I2), N-9 and PVP are utilized to

ing the steps of:

produce powders which exhibit a variety of spermicidal and

(a) fractionating commercially available spermicide N~9

anti-HIV activities.
In order to test and compare the anti-HIV activity of the

to seventeen oligomers by a preparative high pressure liquid

chromatography (HPLC) procedure; and
(b) converting the oligomers or commercially available

25

assay procedure was performed.

N-9 to a high energy coprecipitate with PVP and iodine.
Preferred is a method of preparing a high-energy copre

cipitate composition including the steps of:
(a) fractionating commercially available spermicide non
oxynol-9 (N~9) to seventeen oligomers by high pressure

Procedure for Anti-HIV Activity Assessment
30

liquid chromatography (HPLC);

High-titer suspensions (>106 infectious particles/ml) were
incubated with each compound for 5 seconds, then imme
diately diluted 1:50 onto cultures of human MT-2 cells for
detection of infectivity. Cellular toxicities were observed

(b) adding an N-9 oligomer obtained in step (a) with a
10% or 1% solution w/v of PVP-I in a solvent,

(0) placing the product of step (b) in an oil bath at about
100° C., and allowing the solvent to evaporate.
(d) obtaining a high energy coprecipitate of N-9, polyvi

high energy coprecipitates of the invention, the following

35

and no antiviral activities were expected after the 1:50

dilution, hence all antiviral activity would have resulted
from the 5 second exposure. Infections were monitored by

syncytium (giant cells) formation and Immune Fluorescence

nylpyrrolidone (PVP) and iodine.
energy coprecipitate comprising N-9 oligomers, PVP and

Assay (IFA). This assay utilizes an antiviral antibody with a
?uorochrome attached to it through a covalent bond. Virus
particles get to ?uoresce when viable, and therefore the

iodine to achieve a contraceptive and anti-HIV environment

degree of infectivity is quantitated.

in the vaginal cavity. Thus, the invention provides spermi

The results after 3, 5 and 8 days of incubation are shown
in Table 1. In the control experiment, using the untreated

Also included is a method of treating a female comprising
administering to a female an effective amount of a high

40

cidal and anti-IHV activity with no irritation to the cervical

and vaginal epithelia, and may take the form of an elegant,

virus, the MT-2 cells are 100% infected at the end of 3 days.
A 1% value or less, indicates a complete inactivation of
the virus as measured by the IFA method, i.e. no ?uorescent
particles of the virus exist inside or outside the cells (Table

free ?owing powder.
The invention advantageously provides paper and plastic
products coated with the antiviral composition of the inven
tion.

50

Syncytia (giant cell) formation is assessed by staining
techniques with subsequent microscopic examination. Syn

DESCRIPTION OF THE INVENTION

cytia formation indicates invasion of the MT-2 cells by the

The present invention describes methodology for the
preparation and assessment of new chemical entities with

55

pronounced anti-HIV properties. These chemical entities

The novel composition of the invention comprises a high
energy coprecipitate made from N-9 oligomers, PVP and
iodine. A pronounced synergistic e?ect is obtained between
the compounds, enhancing the anti-HIV activity of the
compounds when in the form of a coprecipitate. Due to the
synergistic effect of the compounds present in the high
energy coprecipitate, the coprecipitate requires less of each

virus.

The method described is that of Monte?ori et al. “Evalu

ation of Antiviral Drugs and neutralizing antibodies to
human immunode?ciency virus by a rapid and sensitive
microtiter infection assay”, J. Clin. Microbiol. 1988, Vol 26:

incorporate N-9 or selected N-9 oligomers, small amounts of
iodine (I2) and the hydrophilic polymer PVP in such a way
as to form high energy complexes, also known as copre

cipitates.

1).

60

231-235, incorporated herein by reference.
Table 1 summarizes the results of anti-HIV activity
assessment of two high energy coprecipitate powders of

PVP-I and N-9. The ?rst was made with oligomers of N-9
with an average molecular weight of 599 and the second
65 with the oligomers of N-9 with an average molecular weight
of 306. Both samples were coprecipitated with PVP, iodine
and one of N9 oligomers mentioned above.

5,492,692
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10
3.24 mg/ml of PVP-I and 0.2 mg/ml of N-9 of an average
molecular weight of 599. This composition achieved a
complete eradication of the HIV virus in 30 seconds.
The use of high molecular weight N~9 oligomers as a

TABLE 1
Inactivation of Cell-Free and Cell-Associated l-lIV-ll

3 days

5 days

Syn
DRUG

cytia

8

days
IFA2

la

IFA

IFA

CPE

CPE

CPE

4-H-

>80%

CPE3

PVP (11.8 mg/ml)
1b

-H+

>80%

PVP (0.236 mg/ml)
2a

—

10%

component of the anti-HIV coprecipitate composition
decreases the systemic absorption of N-9 and therefore N-9
is localized in the vagina and less toxic to the female.
Similar anti-HIV results were obtained with a coprecipi
tate of about 5.8 mg/ml PVP-I and about 0.2 mg/ml N-9 of
10
an average molecular weight of 306. These results represent
an antiviral concentration of free iodine of about 0.03% w/v

(324 ppm). This level of iodine is not irritating to the vaginal
epithelial tissue and desirably has no noticeable brown color.

PVP (3.24 rug/ml)
high MW N-9

(0.2 mg/ml)
>80%

CPE

CPE

15

PVP (0.0648 mg/ml)
high MW N-9

2(0.004 mg/ml)
3a

—

10%

weight of 599, the antiviral properties of the product were

>80%

PVP (5.8 mg/ml)

20

low MW N-9
>80%

CPE

PVP (0.116 rug/ml)
low MW N-9

(0.004 mg/ml)
4a

25

—

mg/mL of N-9 of an average molecular weight of 599 (see

Table 1).

PVP-l (11.8 rug/ml)
>80%

4b

CPE

CPE

Thus, in a preferred embodiment, the presence of 324
ppm iodine in the case of high molecular weight (599) N-9

PVP-I (0.236 rng/rnl)
5a

substantially reduced (see Table l).
A similar reduction of the antiviral properties was also
observed when the product was made from a PVP/N-9 high
energy coprecipitate of 94.2% w/w of PVP and 5.8% w/w of
N-9, at a concentration of 3.24 mg/mL of PVP and 0.2

(0.2 rug/ml)
3b

In contrast to the above results, when no iodine is present
in a coprecipitate composition made with 94.2% w/w of
PVP and 5.8% w/w of N-9, at a concentration of 3.24 mg/mL
of PVP and 0.2 mg/mL of N-9 of an average molecular

—

and 580 ppm of iodine, in the case of the lower molecular

PVP-I (3.24 mg/ml)
high MW N-9

weight N9 (306) importantly adds to the synergistic anti

(0.2 mg/ml)
>80%

CPE

HIV e?ect of the high energy coprecipitate. The iodine and

CPE

N-9 both act in a synergistic manner when complexed with
PVP.

PVP-I (0.0648 mg/ml)
high MW N-9

(0.004 mg/ml)
—

<1%

—

<1%

0%

PVP-I (5.8 mg/ml)

Other solutions made from PVP~I and N9 coprecipitate
35

low MW N49

(0.2 mg/ml)
>80%

CPE

PVP-I (0.116 mg/ml)
low MW N-9

(0.004 mg/ml)
1Details of experimental procedures are given in the test.
2% IFA positive cells
3CPE, viral-induced cytopathic effect was complete.
l-IMW N-9 = 599

"

45

LMW N-9 : 306
IPA = Imuno-?ourescence assay

The data in Table 1 show that PVP-I at a concentration of

in accordance with the invention include 94.2% of PVP-I
and 5.8% of N9 with an average molecular weight of 599.
A further solution made from PVP-I and N-9 coprecipitate
comprises 94.2% of PVP and 5.8% of N9 with a weight
average molecular weight of 306.
The chemical union of the iodine, PVP and several

oligomers of the sperrnicidal agent N-9 with different
molecular weights results in an impressive synergistic action
of iodine and the spermicide N-9 against human immuno~
de?ciency virus (HIV) (Tables 1 and 2).
The coprecipitate of the invention shows that the syner
gism between iodine and N-9 is of such magnitude that

coprecipitate. The coprecipitate composition was 94.2%

solutions with even smaller concentrations of these species
can be used. Again, this is bene?cial as it reduces vaginal
irritation and thus reduces the potential for HIV virus
transmission. Indeed, a complete eradication of the I-HV
virus was obtained when coprecipitates of PVP, iodine and
N-9 solution, containing as low as 58 ppm of N-9 and 940
ppm of PVP-I (94 ppm of iodine), were utilized (see Table

w/w of PVP-I and 5.8% w/w of N-9, at a concentration of

2).

11.8 mg/ml completely inactivated cell-free and cell-asso
ciated HIV-1. This represents approximately an effective
concentration of 1.2% w/v of PVP~I or 0.12% w/v of free

iodine (or 1,200 ppm of 12).
A solution was made from a PVP-I and N-9 high energy

50

TABLE 2
Concentration on Virus

[ug/mL = ppm]

Compound

N9

Syncytia

lFA Position

PVP-I

%

Cells %

No drug

——

—

100

100

KY048
KYOSO

58
117.4

940
10

0
10

0
5

5,492,692
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TABLE 2-continued
KY052

118

0

30

10

Composition of KY Coprecipitates
PVP

KY048
KYOSO
KY052

PVP-I

I2

N-9

%

ppm

%

ppm

%

ppm

%

ppm

0
88.58
88.20

0
885,800
882,000

94.20
0.90
0

940,000
9,400
0

9.40
0.09
0

94,000
940
0

5.80
10.52
11.8

58,000
105,200
118,000

The synergistic etfect against the HIV is so signi?cant that 15

EXAMPLE 1

the above PVP-l/N-9 solution at concentrations as small as

_

58 ppm of N_9 and 94 ppm of iodine are eifective, against

_ _

_

_

The various compositions of coprecipitates are made

the HIV Virus (Table 2)_

according to the following general procedure: Stock solu

In addition to the unexpected synergism between the

tions of approximately 1% w/v OfPVPJ and 1% w/v N'g are

compounds, the coprecipitation of iodine, N-9 and PVP 20 made m ethanol or méthaflol'

_

_

results in the formation of freely ?owing powders which

The N-9 Stock S01l1t10n lsadded dropwise toan ahquot of

enable the prepdmtion of elegant Solid pharmaceutical foi_
mulations with control release properties. The coprecipitate

the PVP-I stock solution with stirring. It is critical that the
FWD soluFlons are mlxed a? a Yer)’ Slow rate- Thus’ the

powders are particularly useful in the design of acceptahie
introduction of the N-.9 solution, into the round bottom ?ask,
solid formulations intended for vaginal, or other appropriate 25 colltalmng the PVP'I’ must be done dropwlse but over a
um
period of not longer than 1.5 hours.

The coprecipitate composition may be administered in the

subseqflemly’ the §°1vfmt is evaporate‘; from the PVOP‘U

form of solid formulations, such as tablets or capsules, or as
ointments, creams or suppositories. In a preferred ernbodi-

N‘9 Sohmon by heatmg 1“ a preheated 011 bath a: 100 C
The temperature must be kept Constant at 100 C- The

ment the composition is administered in the form of a 30 evaporation process should last between 1-2 hours but no

capsuis or tablet

longer than two hours.

Tablets, capsules, ointments, creams or suppositories may
be formulated according methods known in the art such as
those disclosed in Remington ‘s Pharmaceutical Science,

E AMPLE 2
X
If a “glassy” coprecipitate is obtained following the

18th Ed. pp. 1602-1712, incorporated herein by reference. 35 general procedure described in example 1, diethyl ether is
In contrast, N-9 by itself is a viscous liquid which cannot
mixed with lb‘? residue- Upon eYaporation of the diethyl
be formulated as a powder in solid dosage forms such as
ether a crystaume powder 15 obtained
tablets or capsules. N~9 has heretofore been unable to form
elegant tablets or capsules which are preferred by the user
EXAMPLE 3
over creams and suppositories. Additionally, at its generally 40
If a ?nely divided crystallin? powder of the PVP_UN_9

?acgfteil6513:3023; gligrgrsuggglmfmtlgiggzzmiial(gp?ggi;
d 1,y_

an

Hung Q

ffh

’ , at

‘T’ vagm

l

van t‘

At concentrattlops below

g

g

_

i

coPreciPitate is desired, following the Procedure described

p

in Example 1, the residue, received after evaporation

'

described in Example 1, is dissolved in a mixture of metha

PPm nelther 1991115 nor N'9 45 nol/1,4 dioxane (1:4 ratio v/v) and subjected to freeze

am known to lmtate sensltlve membrane llmngs of the

drying for at least 12 hours. A ?ne crystalline powder is

human body. Thus, the coprecipitate powders can be for-

obtained by the frceze_drying step

mulated into drug delivery systems that can release their
active ingredients in a predictable manner without causing
irritation to surrounding membrane linings.

EXAMPLE 4
5O

_

_

t _

The powders of the invention are acceptable to the user
and furnish prolonged protection against AIDS and sexually

commerclally available nonoxynol'g cont'fnmng Sever?
teen oligomers with an average molecular weight of 599 is

transmitted diseases (STDS) with minimal absorption to the

utilized as a component in the general procedure described

Systemic circulation

in Example 1. The oligomer of N9 is isolated by the HPLC
'

ddild'Wal

The main ingredient in the powders of the high energy 55 31:6;62331032565061

BA.

.1

T'.

25852568. waltitralg ‘(A9321 ‘($3013

coprecipitates, described in this invention, is the hydrophilic

Phfmn Res 8, 40'9_4'11_ and Walter B’

giggle;fP23521312221?’ngilqvlvitnacrltls 631226122: gfogfigrilg

Pharm. Res. 8: 403-408, incorporated herein by reference).

only enhances the solubility of the various N-9 oligomers

b Briifgy’ ‘die sepagtaon 1S ?hlevegltiy a prfa’garanve Zor'

but also contributes to the synergistic action of N-9 and 60

ax'

2 60 um (

mm’

pmX

'et at" (1991)

' mm 1' ')'

iodine against the AIDS virus. Thus, in a most important

aspect of the invention, the active ingredients (N-9 and
iodine) are present in the powder in such minuscule quantities that are known not to irritate membrane linings of the

EXAMPLE 5
Stock solutions of N_9 (250 Irig/m1) were prepared in
tetrahydrofuran A 1_() m1 aliquot was Separated on a pm

body‘
65 parative Zorbax-NH2 7 pm column, 250 mm><2l.2 mm ID,
using a linear solvent gradient from 98% A-2% B to 50%
The following examples are given to illustrate the inven
A—50% B in 90 min., where A=tetrahydrofuran:hexane
tion, but are not to be construed as limiting.

5,492,692
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(20:80, v/v) and B=water:2-propanol (10:90, v/v) delivered

Vehicle:
0.9% sodium chloride USP solution (SC)

at 9.9 ml/rnin at ambient temperature and detection at 280
nm. The HPLC system used was a Waters HPLC system

Preparation:

(Millipore, Waters Chromatography Division, Millford,

Following instructions provided, a 0.323 mg portion of

Mass.) consisting of two Waters Moldel 510 I-IPLC pumps,
a Waters Model 680 gradient controller, a Waters Model 440
Absorbance detector (280 nm), and a Waters Model SE120

the test article was solubilized in 100 ml of SC. The
solution was kept refrigerated until use. Each dosing
day, a suf?cient amount of the test article solution was

dual channel recorder. Samples were introduced via a Rheo

removed and brought to room temperature. The vehicle

dyne Model 7125 loop injector equipped with a 100 pl loop
onto the HPLC column. Seventeen oligomers were col

10

lected, concentrated and reinjected onto the analytical sys
tem for further puri?cation. The 599 molecular weight
fraction and 305 molecular weight fraction were separated
from the other fractions.
A 10% or 1% solution of w/v of PVP-I and the MW 599

Animal Manaqement:
Five healthy male rabbits of the New Zealand White
variety were obtained from USDA licensed suppliers. These
animals were acclimated to the laboratory.
Rabbits, identi?ed by ear tag or tattoo and weighing 2.5
kg to 2.6 kg, were individually housed in suspended cages
and received a commercially pelleted rabbit feed on a daily

fraction of the compound of nonoxynol-9 (N9) (isolated as
set forth above) in absolute ethanol (methanol) was made.
Both solutions were added via dropping funnels into a round

bottom ?ask. It is important in this step to allow the dropping
of the two solutions to continue for 1.5 hours. Thus the
addition of the two solutions must take place slowly.
To an oil bath which had been preheated to 100° C., the
?ask was placed and the solvent allowed to evaporate. It was
important to make sure that the temperature was well

basis; tap water was freely available. No diet or water
analysis was performed since there were no contaminants

suspected that could interfere with this study. Animal hus
bandry and environmental conditions conformed to current
standard operating procedures which are based on the
“Guide for the Care and Use of Laboratory Animals,” NIH
Publication No. 85—23.

controlled during the evaporation process. The evaporation
process should take between 1 and 2 hours. The evaporation
should not take place longer than 2 hours.
A high energy coprecipitate of the compounds is obtained.
Examples 6—8 show formulations of the high energy
coprecipitate of the invention.

Experimental Procedure
30

EXAMPLE 6

prepuce. (Note: Not all of the test article solution or control

vehicle remained in contact with the penile tissue.) Animals
were maintained in restrainers for 4 hours and then returned

average molecular weight of 599 in a tablet formulation.
40

next application) and also the day following last treatment in
accordance with the following scoring scheme.
45

EXAMPLE 8

A high energy coprecipitate providing anti-HIV protec—
tion at an effective concentration of about 58 ppm of N-9 and 50
940 ppm of PVP-I or 94 ppm of iodine in a cream formu

EXAMPLE 9
55

and completed in seven days.
Materials: The high energy coprecipitate composition was

Results
Clinical Observations: All animals appeared clinically nor

Body Weight and Macroscopic Examination:

Rabbit

identi?ed and handled as follows:

Test Article:

Controlled room temperature

3=moderate redness and swelling
4=marked redness and swelling

mal throughout the study
Body Weight and Macroscopic Examinations:

was conducted in the rabbit. The purpose of this study was
to evaluate the potential for mucosal irritation of a solution
administered to penile tissue. Animal treatment was begun

Spermicidal/anti-HIV agent
Storage Conditions:

0=no change
1=slight redness/or swelling
2=moderate redness, slight swelling

Mucosal irritation was based on a comparison between
test and control scores. Average irritation scores of 2 or
greater were considered as slight irritation; scores of 3 or
greater were considered as signi?cant irritation.

lation.

A multiple dose penile irritation study of the high energy
coprecipitate composition of the invention identi?ed below

to their respective cages.
Each animal was observed daily for general health. Rab’
hits were weighed just prior to ?rst treatment and at study
termination. The penile tissue was observed for signs of

irritation the day following each application (prior to the

A high energy coprecipitate providing anti-PHV protec
tion at an effective concentration of about 5.8 mg/ml PVP-I

and 0.2 mg/ml N-9 of an average molecular weight of 305
in a capsule formulation.

Three rabbits each received a single 2.0 ml treatment of
the high energy coprecipitate solution on each of 5 consecu
tive days. Two additional rabbits received a similar dose of
the control vehicle. The appropriate test article solution or

control vehicle was applied to the penis and surrounding

A high energy coprecipitate composition of 940.09% I
w/w and 11.8—5.8% N-9 w/w. The high energy coprecipitate
provides anti-HIV protection at an eifective concentration of
about 3.24 mg/ml of PVP-I and 0.2 mg/ml of N-9 of an
EXAMPLE 7

(SC) was dosed “neat” to serve as the control.

Condition of Extracts:
SC Test: clear brown
SC Control: clear
Methods

65

Weight (kg)

Number

Day 0

75384 T
75303 T

2.4
2.6

Day 5 Macroscopic Observations of Vagina
2.4
2.6

Macroscopically normal
Macroscopically normal

5,492,692
15
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-continued

Rabbits, identi?ed by ear tag or tattoo and weighing 2.4
kg to 2.7 kg, were individually housed in suspended cages
and received a commercially pelleted rabbit feed on a daily

Body Weight and Macroscopic Examination:

Rabbit

Weight (kg)

basis; tap water was freely available. No diet or water
5

Number

Day 0

75296 T

2.5

2.6

Macroscopically normal

75302 C

2;;

2'8

sligm redness

75322 C

Day 5 Macroscopic Obsemm-ons of vagina

25

2'6

.

.

.

analysis was performed s1nce there were no contammants

suspected that could interfere with this study. Animal hus
- bandry and environmental conditions conformed to current

Mamsmpicany mm

standard operating procedures which are based on the

10 “Guide for the Care and Use of Laboratory Animals,” NIH

(Tzjéffml

Publication No. 85-23.

_

Experimental Procedure:

Evaluanon

_

_

_

f

_

Three rabbits each received a single 2 ml instillation of the

The avarage mucosal lmtanon Scope 0? the test ammals
was 0 as compared to O for the control anlmals. There was
.

.

.

.

.

.

high energy coprecipitate solution into the vagina for 5
15

.

.

. .

.

.

.

.

consecutive days. Two additional rabbits received a similar

no evidence of sigm?cant irritation in the test or control

_

_

,

tissues of the rabbits_

dose of the control solution. The appropriate test article or

Conclusion: Under the conditions of this study, the high

control Soluuon was Introduced. Into the_ vagmal vault

energy coprecipitate composition was not considered an
through a 50ft hlbbcr catheter mclstchcd Whh thc Prcpam
initam to the penile mucosal tissues of the rabbit
20 tion. Animals were returned to their cages after treatment.
Each animal was observed daily for general health and for

EXAMPLE 11
'

_

_

_

external signs of irritation around the opening of the vaginal

_

_ _

vestibule. Rabbits were weighed just prior to ?rst treatment

A vaginal irrétagonstudyiof the1 h1g2 ecrlieggy coprecipitate
composltlon 0 t 6. mvcnnon 1 en“ 6

and at study termination

e ow was con' 25

ducted 1n the rabbit. The purpose of the study was to
.
.
. .
.

On the day following the last treatment the rabbits were
.
.
. .
.
.
euthanatized by an intravenous IIIJCCHOII of a sodlum pen

evaluate the potential for mucosal tissue irritation of a

b b. all b

d

h

_ d

E h

_

d

material administered intravaginally to rabbits for 5 conF0 at It ase em afmsla rug‘ ac V851“ was rem°ve_
secutive days. Animal treatment began and was completed
1“ tow’ opened longltudmany and exammed macroscopl'
within a 5 day pen-0d
3O cally for signs of in?ammation. Representative sections of
Materials: The high energy coprecipitate composition of the
each vagina were preserved in 10% neutral buffered forma
invention was identi?ed and handled as follows:
lin and histologically processed (hematoxylin and eosin
Test ??iClBI
stain) for microscopic evaluation by a board certi?ed

Spermicidal/anti~HIV agent
Storage Conditions:

pathologist. The assessment for mucosal irritation potential
-

35 was based on the histopathological ?ndings.

Controlled room temperature

Results and Clinical Observations: All animals appeared

Control Article:

clinically normal throughout the study.
Weight (kg)
Rabbit Number/Group
75333 Test
75342 Test
75337 Test
75339 Control
75360 Control

0.9% sodium chloride USP solution (SC)
Preparation:

OBSERVATIONS

DAY 0

DAY 5

DAY 1

DAY 2

DAY 3

DAY 4

DAY 5

2.6
2.6
25
2.5
2.6

2.5
2.6
2.6
2.5
2.6

O
0
0
O
0

0
0
O
0
0

0
0
O
0
0

O
0
O
0
0

0
0
0
0
0

50 Microscopic Evaluation: The average mucosal irritation
score for the test animals was 5 as compared to 6 for the

A 0.323 mg portion of the test article was s olubilized in

lOO ml of SC. The solution was kept refrigerated until

control animals- Individual results of the Pathology ?nd

h1g3 appear in the attached microscopic evaluation

use_ Each dosing day, a Su?icicnt amount of the test 55 Conclusion: Under the conditions of this study, the average
article solution was removed and brought to room
mucosal irritation score of the vaginal tissues treated with
temperature’ The vehicle (SC) was dosed “neat” to
the test article solution was within acceptable limits. The
Serve as the contrOL

test article was not considered an irritant to the vaginal

Condition of Solution
SC I t

1 ti

_ 1

mucosal tissue of the rabbit.
b

65 so u on‘ 0 car rown

SC control: clear
Methods: Ahlmal Management

60 II. PVP-I/N-9 coated paper products
The data set forth above shows that the chemical union of

iodine, polyvinylpyrrolidone (PVP) and several oligomers
of the spermicidal agent nonoxynol-9 (N-9) with different
Five healthy female rabbits of the New Zealand White 65 molecular weights results in animpressive synergistic action
variety were obtained from USDA licensed suppliers. These
of iodine and the spermicide N-9 against human immuno
animals were acclimated to the laboratory.
de?ciency virus (HIV) (Tables 1 and 2).

5,492,692
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Alternatively the paper may be coated by any coating
process, including straight or roll coating procedures. The
following coating methods may also be used.

The coprecipitation of iodine, N-9 and PVP results in a

synergism of such magnitude that very small concentrations
of these chemical species posses good anti-HIV properties
(Table 2). Indeed, complete eradication of the HIV-virus was
obtained when such coprecipitates were used containing
concentrations of PVP-I and N-9 of 940 ppm (94 ppm of

COATING TECHNIQUES
1. Brush Coating

iodine) and 58 ppm, respectively.
In addition to the unexpected synergism between the
above chemical species, the coprecipitation of iodine, N-9
and PVP results in the formation of freely ?owing powders
which enable the preparation of elegant solid pharmaceutical

2. Roll Coating
Pressure
Kiss
Reverse Roll

formulations which otherwise would be very di?icult to

produce.

3. Rod Coating
4. Knife Coating
5. Print Coating

One application of the antiviral composition of the inven
tion is the production of paper coated products or sheets of
paper which possesses the ability to destroy the HIV virus
instantly upon contact with biological ?uids containing this
virus. Such products, for example include, but are not
limited to coated surgical gowns, paper masks, paper made
bed covers and other paper liners utilized in hospital beds
and on physician’s examination tables. Any paper product
can be coated with the high energy coprecipitate powder of
the invention.
Exposure to blood borne pathogens has always been a
primary concern for the community of individuals whose

occupations require physical contact with tissue and body

Flexo
Gravure
20

6. Spray Coating
Cold Spray
Hot Spray
Electrostatic Spray
7. Dip Coating
For example, the high energy coprecipitate of the inven

25

tion may be spray coated onto the paper material with a

Binks spray gun model Mach 1 HVLP. When coating or

?uids. This concern has heightened due to the alarming
increase in the incidence of Human Immunode?ciency Virus
(HIV) infections. See Bartlett, J. G. “HIV Infection and

spray coating, the high energy coprecipitate of the invention
or other drug the “coat weight” (weight per unit area of

and includes physicians, nurses, technical staff as well as

“dry” non-volatile material which is applied to the paper
substrate) is in the range of 2-30 g/m2 based upon 50—75%
drug concentration in the coating. In a preferred embodiment
the coat weight is in the range of 2-8 g/m2 based upon

ancillary personnel such as housekeeping staff. The Centers

50-75% drug concentration in the coating.

Surgeons”, Current Problems in Surgery, Wells, S. A., ed.
Moseby~Year Book, Inc. 1992.

30

The community of concerned individuals is broad based
for Disease Control (CDC) has reported on 137 cases in

which HIV was probably acquired through occupational

35

material. These compounds include:

exposure. 37 of these cases, which includes 4 surgeons have

Acylclovir (Burroughs & Wellcome Corp.)——dose range:

been strongly con?rmed. The majority of these infections

200-1000 mglcmz.

are thought to have occurred as the result of hypodermic or

surgical needle punctures. See, CDC. “Recommendations
for Assisting in the Prevention of Perinatal Transmission of

Ribavirin (ICN Pharrnaceuticals)——dose: about 20
40

Human T-Lymphotrophic Virus Type lII/Lymphadenopathy
Associated Virus and Acquired Immunode?ciency Syn

mglcmz.

Retrovir (AZT) (Burroughs & Wellcome Corp.)—dose:

200-1500 mglcmz.

drome”, MMRW 1985, 31:577—580.
In addition, the CDC has documented at least 3 healthcare
workers who have acquired I~HV through cutaneous or
rnucocutaneous contact. See, CDC, “Update: Human Immu
node?ciency Virus Infection in Health-Care Workers

Other drugs which may be effective as anti-HIV and/or
anti-bacterial materials may also be coated onto the paper

45

Interferon alfa-n3 (Purdue Frederick, Inc.)—dose: about
0.5 million I.U. (I.U.=International Units)
Chlorhexidine=antirnicrobial agent (2-4%)
PVP-Bromine
In a preferred embodiment the coating material is the high
energy coprecipitate PVP-I-N9 combination. Mixtures of
the antiviral/antibacterial agents are also preferred.
When PVP-I-N9 coprecipitate is applied to the paper

Exposed to Blood Infected Patients”, MMRW 1987,
36:19:285-289. Such transmission is thought to occur via
breakdown in the integrity of cutaneous, rnucocutaneous
barriers with eventual exposure and infection of the host’s
immune cells. This type of transmission can occur from a

material a lower concentration of the drug is needed to be

myriad of sites including open cutaneous wounds, dermatitis

effective. A coat weight of 5.40 mg/cm2 is more preferred
when a PVP-I-N9 coprecipitate is applied to paper. A lower
concentration of PVP-I-N9 coprecipitate translates to lower
coat weights at 75% drug concentration or lower drug

with exudant, cuticular infections, etc.
The process of making the coated paper products of the
invention is set forth below. The present invention broadly
encompasses any paper product comprising an anti-PHV and
antibacterial composition. In a preferred embodiment the
paper product comprises anti-HIV and antibacterial compo

55

concentration or both.

Alternatively, any drug or the high energy coprecipitate
can be attached to the surface of the paper by a microen

sition which is applied to the paper product as a microen

capsulation process. Microencapsulation is the enclosure of

capsulated coating.

an inner material, such as a drug, within an outer material

In a most preferred embodiment the anti~HIV and anti

bacterial composition is the high energy coprecipitate of
PVPI/N-9. Mixtures of the drug (PVPI/N~9) were made and
these were utilized as coating solutions (Tables 3 and 4). A 65

thin layer of the drug was formed by spray-coating of the
various solutions onto the paper.

processed into the form of rnicrospheres in the micron size
range of 0.1-1.50u. The outer material which forms the
rnicrosphere is designed to be a protective coating and can
be formulated with semipermeable membrane or slowly
dissolving properties to achieve controlled release of the
inner material.

5,492,692
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One microencapsulation technique that can be used is
dissolving the inner material in hydrophobic liquid and then
fornring an emulsion with a water soluble polymer with high
speed mixing. Droplets of inner material in a hydrophobic

TABLE 3-continued
COMPONENTS FOR FILM COATING SOLUTIONS
2. Aluminum lake
3. Red iron oxide

liquid surrounded by rnicrospheres of water soluble polymer
are then formed.

4. Dyes

Another microencapsulation technique. is heating a low
melting inner material to a molten state. This molten state
material is then added to an aqueous solution of water

soluble polymer forming an emulsion with high speed
mixing. Droplets of molten inner material encased in micro

PLASTICIZERS:
. Glycerin

. Propylene glycol
. Polyethylene glycol

10

. Triacetin

. Triethyl citrate

spheres of water Soluble polymer are then formed. Microen
capsulation solutions can be coated on a variety of substrates

. Diethyl phthalate
. Dibutyl phthalane

with conventional coating techniques. In a preferred

GLIDANT S:

embodiment a drug or the high energy coprecipitate com
position is microencapsulation coated onto the paper mate

rial.
Tables 3 and 4 describe preferred embodiments of the
components utilized for ?lm coating solutions and examples

of their compositions, respectively.

. Talc

. Magnesium stearate

VEHICLES:
. Alcohols

20

. Ketones
. Esters

In a preferred embodiment the coated-paper was prepared
as follows: Paper taking the form a commercial surgical
paper gown was sprayed by a solution of the PVP-I/N-9

(drug) in ethanol-water (8:1).
The composition of coating solution is represented by

. Chlorinated hydrocarbons
. Water

*Note:
25

example D of Table 4 and was as follows: Drug (PVP-I/N-9)

Eudragit RL - copolymer of acrylic and methacrylic acid esters with low
content of quaternary ammonium groups.

75% w/w; HPMC 6% w/w; PEG 1450 14% w/w; talc 15%

Eudragit E - copolymer of dimethyl aminoethyl methacrylate and neutral
methacrylic acid ester.

w/w and Tween 80-6% w/w.
The ?nal concentration of the total amount of drug on the
paper was found by titration of iodine (using the United

Table 4 below includes some examples of preferred
embodiments of the coating solutions of the invention.

States Pharrnacopeia) to be 4.05 mg/cm2. Of this amount
0.375 mg is iodine, 0.25 mg is N-9 and the remaining (3.43
mg) is PVP. As little as 0.5 mg/cm2 of the drug (PVP-I/N-9)
is needed to kill completely the virus (1X105 infectious,
cell-free virus particles per 0.1 ml of contaminated blood).

TABLE 4
EXAMPLES OF COATING SOLUTIONS

If one considers that approximately one to two drops of
blood (0.05—0.1 ml) are to be absorbed per square centimeter

A

antiviral composition

(cm2) of the coated paper. Table 1 shows approximately 300
pg of the drug are needed to kill the virus in 0.1 ml of blood.

Thus, if 1 cm2 of paper absorbs two drops of blood (0.1 ml),
the e?ective amount of antiviral compound required per cm2

HPMCAS
40

the art.

50

50—75%

HPMCP

6-20%

Methylene chloride/Ethanol

(1:1)

antiviral composition

50-75%

HPMC
PEG 6000

6-20%
12-25%

EC or I-IPMCP

5-15 %

Methylene chloride/ethanol

(1:1)

antiviral composition

POLYMERS:
55

2. I-Iydroxypropyl Methyl Cellulose
Phthalate (HPMCP)
. Hydroxypropyl Cellulose (HPC)
. l-Iydroxypropyl Methyl cellulose

50-75%

HPMC
REG 1450
Talc
Tween 80

6—l0%
9-25%
7-10%
5—7%

Water/ethanol

(8: 1)

E_

Acetate Succinate (HPMCAS)
60

. Polyethylene glycol (PEG 1450, PEG

1. Titanium dioxide

(20:80)%

2

COMPONENTS FOR FILM COATING SOLUTIONS

8000, PEG 6000)
9. Ethyl Cellulose (EC)
COLORANTS:

3.0—7.0%

C

inventions.

. Eudragit RS PO*
. Eudragit R.L PO*
. Eudragit E 100*

Talc

antiviral composition
45

of the coating solutions for paper coated products of the

. I-Iydroxypropyl Methyl Cellulose (HPMC)

10-20%

18-50%

B

The following tables provide examples of the components

TABLE 3

50-75 %

Triethyl citrate

Water/Ethanol

of paper is about 0.3 mgIcmZ-about 0.6 mglcmz.
Film coating solutions may contain polymers, colorants,
glidants, plasticizers, and vehicles known to those of skill in

PO means powder supply
100 means granulate supply

65

antiviral composition

50-75%

Eudragit RL PO

10-15%

or Eudragit RS PO
PEG 6000
Talc
Tween 80

12-25%
7-10%
5-7%

Water/ethanol
F

(7:3)

5,492,692
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TABLE 4-continued

A blinded study was designed to address the irritability of
antiviral powder of the invention when utilized as a topical
agent on the epidermis of the hand. Dermatologic contact

EXAMPLES OF COATING SOLUTIONS

was achieved via the use of commercially available, non
antiviral composition
Eudragit E 100

50-75%
5-10%

treated latex surgeon’s gloves to which 250 milligrams of

PEG 6000
Talc
Tween 80
Water/ethanol

12-25%
7—l0%
5—7%
(2:8)

the right or left glove. The remaining gloves remained

antiviral powder was applied to the inner surface of either
untreated.

The study population consisted of 25 healthy volunteers.
10

Males or females between the ages of 18-75 years who will

be recruited for this study. Only individuals with no existing
rashes, eczema, abrasions, cuts or dermatologic abnormali

Coating solutions may be applied to the surface of the any
paper product or between plys of the paper products.
ANTI-HIV STUDY

ties were included in the study.

Control gloves and treated gloves were provided to the
volunteers. Distribution and collection of the gloves prior to
and after exposure was coordinated by the principal inves»
tigator. Each treatment glove (latex or nylon) had approxi
mately 250 mg of antiviral powder added to the inside

A study was conducted to test the anti-HIV properties of
paper materials coated with the anti-HIV compound of the
invention.
Tests were performed by placing 0.5 ml of virus (HIV
llllB), >106 infectious particles/ml) in the center of an area
of a surgical gown which had been treated with the anti-HIV

lining.
In keeping with current standards and providing addi
tional barriers for protection of healthcare workers, a sample
of PVP-I/N-9 containing 940 ppm of I2 and 62,000 ppm of
N9 was prepared which was placed in latex surgical gloves

PVP-I/N-9 high energy coprecipitate compound of the

invention. The drop of virus was swirled until it covered an
area of approximately 2 inches in diameter. After a 2 minute
incubation, 50 ul of the virus suspension was removed from
for use as additional protection to be used in medical
the treated area of the surgical gown and diluted in 1:100 in 25 treatment, and in surgical and handling procedures.
Antiviral compound was in powder form and of the same
growth medium. Fifty microliters of diluted virus was then
consistency of commercially available glove talc or corn
added to 200 111 of MT-2 cells in a 96-well plate. Infections
starch. Control gloves were of the same material (latex or
were monitored by syncytium (giant cell) formation, immu
nylon) and were not treated with any additives.
no?uorescence assay (IPA) and p24 assay for a period of 11

At the conclusion of the study all materials including
exposed gloves were returned. Clinical assessment of each
volunteer was made by a board certi?ed dermatologist.

days. As a separate control, the original virus suspension
was tested before adding it to any materials (i.e. untreated
virus). In addition, an untreated gown was tested which was

not treated with PVP-I/N-9 high energy coprecipitate.
Results: Untreated virus and virus placed on control gown

fabric produced syncytia and complete cell killing after 5

35

volunteers’ dermatologic condition and determined that no
preaexisting condition existed, the volunteer were allowed to

days of incubation with MT-2 cells. Virus that had been
placed on both of the treated gown fabrics produced no

syncytia after 11 days, and all the cells were negative by [FA
and p24 assay for viral antigen synthesis, indicating that all
infectious viral particles had been inactivated. Thus, the
treated paper products inactivate HIV virus and provide a

initiate the study. Photographs (135 mm, 100ASA) were
40

Volunteers’ dermatologic condition were assessed by the
physician at seven day intervals during the exposure period

ll]. PVP-I/N-9 coated plastic products
45

accompanied by written evaluations of the physician.
Any abnormal dermatologic condition such as itching,
50

ing male and female condoms.
Current Occupational Safety and Health Administration
55

ally being reviewed and the development of additional
safety and protection devices are being investigated. These

was withdrawn from the study. Clinical assessment and
evaluation by the physician was made within 24 hours.
Photographs were made of the volunteers hands, as
described earlier, for documentation.

An assessment was performed of the dermatologic safety
and allergenic properties of the antiviral powder with spe
ci?c kill properties for the human immunode?ciency virus.

include devices or barriers that contain antiviral compounds.
A study was performed to evaluate the dermatologic
tolerance of the antiviral powder of the invention when used
as an antiviral barrier worn topically inside surgical and

Each volunteer was examined by the physician immedi

ately prior to exposure for detection of any preexisting
dermatologic condition. Twenty-?ve human volunteers, 16

medical gloves. The study examined the dermatologic aller
genic properties of the powdered compound when worn by
individuals for extended periods of time. The results of the
study are equally applicable to safety of condoms coated
with the antiviral composition of the invention.

eczema, swelling, numbness or any other abnormality expe
rienced by the volunteer was required to be reported to the

principal investigator immediately and any such volunteer

(OSHA) standards regarding blood borne pathogens
requires the use of gloves in the processing and handling of
any blood and/or body ?uids. These standards are continu

and at the end of a seven day period following the exposure
period. Each volunteers’ hands were photographed imme
diately following the 21 day exposure period in the same
fashion as described above. All clinical assessments were

Any plastic product may be covered with the antiviral

powder of the invention, including, for example, plastic
gloves, including surgical gloves and latex condoms, includ

made of each hand on both the dorsal and ventral surface of
each volunteer. Volunteer codes and dates were included in

the photographs.

barrier to HIV virus.

In accordance with the present invention, it is also desir
able to coat plastic, polymer or latex products with the
antiviral/antibacterial compound of the present invention.

Each volunteer was examined by the physician immedi
ately prior to exposure and was assessed for any pre-existing
dermatologic condition. Once the physician has assessed the

65

male, 9 female with average age of 36 years, were exposed
to 250 mg of the compound contained in powder free
examination gloves. Powder free examination gloves with
out the antiviral agent was worn on the opposite hand and
served as a control.

5,492,692
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Gloves were worn by the individuals for 4 hours/day for
21 consecutive days. Dermatologic examinations were per

compound is the PVP-I/N9 compound of the invention.

formed at 7 day intervals. Results: All 25 subjects completed

operation, or to the exact compositions, methods, proce
dures, products or embodiments shown and described, as

The invention is not to be limited to the exact details of

the 21 day exposure period with a total exposure time of

2,224 hours (Table 5). Average exposure time per day was
4.21 hours with the greatest exposure being 5.24 hours/day
(Table 5). Dermatologic evaluations revealed no allergenic
or abnormal derrnatologic conditions arising from the expo

obvious modi?cations and equivalents were apparent to one
skilled in the art. The invention is therefore to be limited

only by the full scope which can be legally accorded to the

appended claims. All publications cited herein, are incorpo~
rated herein by reference in their entirety.

sure to the antiviral compound. Two subjects were reported

to have known derrnatologic reactions with commercially

We claim:

available gloves treated with talc or cornstarch. Examina
tions from these subjects were negative.

1. A coated paper product comprising a paper product
coated with a high energy coprecipitate of nonoxynol oli
gomer and polyvinyl pyrrolidone polymer and iodine, or

It was concluded that the use of an antiviral compound

designed for the use in surgical, examination or handling
gloves as an antiviral barrier was shown not to cause any

derrnatologic reactions or abnormalities to the hands. The
PVP-I/N-9 drug will provide an additional eifective and safe

15

simultaneously precipitated in said high energy coprecipi
tate exceeds the individual effect of said compounds, and

barrier for individuals whose occupations require the physi
cal contact with human tissue and/or body ?uids. This group
of individuals is not limited to but includes physicians and
surgeons, nurses and ancillary personnel such as housekeep

wherein said high energy coprecipitate has antiviral activity
against human immunode?ciency virus-1 (HIV-1) in an
20

TABLE 5
HAND IRRITABILITY ASSESSMENT OF THE ANTI
VIRAL POWDER (PV-IlN-9) IN HUMAN VOLUNTEERS

SHOKI‘EST EXP. (HR)
LONGEST EXP. (DAY)
SHORTEST EXP. (DAY)
LON GEST AVG. EXPJDAY
LEAST AVG. EXP/DAY

16
9
36
13
62
18
35
14
61
18
38
12
62
19
2224
528
88.96
4.21
110

30
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5. The product of claim 1, wherein said high energy
coprecipitate composition is applied to said paper product as
a microencapsulated coating.
6. The product according to claim 1, wherein said copre
cipitate is a powder.
7. The product according to claim 6, wherein said powder
is a ?nely divided crystalline powder.
8. The product according to claim 1, wherein said PVP-I
comprises about 0.09—9.4% w/w of iodine.
9. The product according to claim 1, wherein said PVP-I

Thus, the plastic products of the invention advanta

geously, provide protective, non-irritating antiviral barriers
50

product generally incorporated an anti-HIV and antibacterial

composition. These compounds include:
Acylclovir (Burroughs & Wellcome C0rp.)—dose range:

.

11. The product according to claim 1, wherein said
55

mg/cm2.

Retrovir (AZT) (Burroughs & Wellcome C0rp.)—dose:

200-1500 mglcmz.
Interferon alfa-n3 (Purdue Frederick, Inc.)—dose: about
0.5 million LU. (I.U.:International Units)
Chlorhexidine=antirnicrobial agent (2—4%)
PVP-Bromine
In a preferred embodiment the anti-HIV and antibacterial 65

composition is applied to the plastic product as a coating. In

comprises an antiviral concentration of free iodine of about
0.03% w/v or 300 ppm complexed with PVP.
10. The product according to claim 1, wherein said PVP-I
comprises an effective antiviral concentration of free iodine
of about 0.0094 w/v of iodine or 94 ppm complexed with
PVP.

Ribavirin (ICN Pharmaceutica1s)~—dose: about 20

a most preferred embodiment the anti-HIV/antibacterial

4. The product of claim 3, wherein said high energy
coprecipitate composition is sprayed onto said paper product
in the form of a coating comprising 50—75% by weight

antiviral composition, 6—10% polymer by weight, 9—25% by
weight plasticizer, and 7—10% by weight ?ller.

4.00

200—l000 mglcmz.

brush coating, roll coating, pressure coating, kiss coating,
reverse roll coating, rod coating, knife coating, print coating,
?exo coating, gravure coating, spray coating, cold spray
coating, hot spray coating, electrostatic spray coating, dip

coating, and microencapsulation coating.

84
23
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5.24

for use in the work place, hospital, home and wherever
antiviral and antibacterial barriers are required. The plastic

MT~2 assay.

2. The product of claim 1, wherein in said paper product
is selected from the group consisting of surgical gowns,
paper masks, paper-made bed covers, and paper liners
utilized in hospital beds and physician’s examination tables.
3. The product of claim 1, wherein said high energy
coprecipitate composition is coated on said paper product by
a coating method selected from the group consisting of

ing personnel.

TOT. N0. of MALE SUB].
TOT N0. of FEMALE SUB].
AVG. AGE of SUB].
SD. of AGE
OLDEST SUB].
YOUNGEST SUB].
AVG. AGE of MALE SUB].
SD. of MALE SUB]. AGE
OLDEST MALE SUB].
YOUNGEST MALE SUB].
AVG. AGE of FEMALE SUB].
SD. of FEMALE SUB]. AGE
OLDEST FEMALE SUBJECT
YOUNGEST FEMALE SUB].
TOT. NO. OF EXP. HRS
TOT. NO. OF EXP. DAYS
AVG. EXP. per SUB]. (I-Ir.)
AVG. EXPJSUBJJDAY (Hr)
LONGEST EXP. (HR)

nonoxynol oligomer and polyvinylpyrrolidone-iodine com
plex (PVP-I), wherein the combined effect of the compounds

nonoxynol oligomer of said coprecipitate comprises from
about 5.8 to 11.8% w/w of nonoxynol-9 oligomer.
12. The product according to claim 1, wherein said
coprecipitate is present at a concentration of about 3.24
mg/ml of PVP-I and about 0.2 mg/ml of N9 oligomer of an
average molecular weight of 599.
13. The product according to claim 1, wherein said
coprecipitate is present at a concentration of about 5.8
mg/ml PVP-I and about 0.2 mg/rnl N-9 oligomer of an
average molecular weight of 306.
14. The product according to claim 1 wherein said copre
cipitate is present at a concentration of about 5 .8 ppm of N-9
oligomer and about 940 ppm of PVP-I or 94 ppm of iodine.

5,492,692
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15. The product according to claim 1, wherein said
nonoxynol oligomer is an nonoxynol-9 oligomer with an
average molecular weight of 599.
16. The product according to claim 1, wherein said

50—75% anti-HIV and antibacterial composition concentra
tion in the coating.

nonoxynol oligomer is nonoxynol-9 oligomer comprising

coated with a high energy coprecipitate of nonoxynol oli

oligomers of N-9 having a range of molecular weight of each
oligomer from about 264 to about 1000.
17. The product according to claim 1, wherein the percent
of polyvinyl pyrrolidone ranges from about 88% to about
97%.
18. The product according to claim 1, wherein the average

gomer and polyvinyl pyrrolidone polymer and iodine, or
nonoxynol oligomer and polyvinylpyrrolidone-iodine com
plex (PVP-I), wherein the combined eifect of the compounds
simultaneously precipitated in said high energy coprecipi~

molecular weight of said polKvinyl pyrrolidone ranges from

wherein said high energy coprecipitate has antiviral activity
against human immunode?ciency virus-1 (PHV-l) in an

22. A coated plastic product comprising a plastic product

tate exceeds the individual eifect of said compounds, and

about 2,500 to 1,100,000.
19. A paper product coated with an anti-HIV and anti

bacterial composition.
20. The product of claim 19, wherein said anti-HIV and
antibacterial composition is applied to said paper product as

a microencapsulated coating.
21. The product of claim 19, wherein said anti-HIV and
antibacterial composition is applied to said paper in the form
of a coating with a coat weight of 2-30 g/m2 based upon a

15

MT'2 assay.

23. The product of claim 22, wherein said plastic product
is selected from the group consisting of gloves, plastic
liners, and condoms.

